Compare VOXR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOXR | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.5M | 316.0M |
| IPO Year | 2022 | 2021 |
| Metric | VOXR | PROK |
|---|---|---|
| Price | $5.99 | $1.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.90 | ★ $7.40 |
| AVG Volume (30 Days) | 461.2K | ★ 1.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $60.51 | N/A |
| Revenue Next Year | $44.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $3.39 | $1.30 |
| 52 Week High | $6.70 | $3.48 |
| Indicator | VOXR | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 72.37 | 56.09 |
| Support Level | $4.97 | $1.56 |
| Resistance Level | $5.87 | $2.59 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 85.44 | 82.61 |
Vox Royalty Corp is a returns-focused mining royalty and streaming company. It holds a diversified portfolio of several royalties and streams, including producing and development stage assets, with primary exposure to gold and select industrial metals across top-tier mining jurisdictions. Vox is organized into two operating segments, consisting of acquiring and managing royalty interests; and acquiring and managing streams and other interests. Maximum revenue is generated from its Royalty Interests segment. The majority of the company's portfolio of royalty, streams, and other interests by asset count is located in Australia, Canada, and the United States, of which the maximum revenue is derived from its assets in Australia.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.